The investigational product (ALLOD-2), is a combination of two marketed drugs used for the acute treatment of migraine due to the discovery of biologically and clinically relevant affinities for a new target for pain. Both drugs are used at a significantly lower dosage compared to the dosage that has already been approved for the marketed indications.